Highlights SK Biopharmaceuticals Co., Ltd.

Equities

A326030

KR7326030004

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-06-02 pm EDT			5-day change	1st Jan Change
85,800 ^KRW	+0.47%		+2.26%	-14.54%

May. 10	SK Biopharmaceuticals Turns to Profit in Q1 as Sales Jump 88%	MT
Jan. 30	SK Biopharmaceuticals Swings to Profit in Q4	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

SK Biopharmaceuticals Turns to Profit in Q1 as Sales Jump 88%	May. 10	MT
SK Biopharmaceuticals Swings to Profit in Q4	Jan. 30	MT
SK Group Advances Net Zero Transition via Key Renewable Energy Deal	Nov. 27	MT
SK Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	23-10-12	CI
Sk Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data on IKZF2 Protein Degrader Program and Moped Molecular Glue Screening Platform At the 20Th Annual Discovery on Target Conference	23-09-26	CI
SK Biopharmaceuticals Co., Ltd. acquired remaining 605 stake in ProteoVant Sciences, Inc. from Roivant Sciences Ltd..	23-08-30	CI
SK Biopharmaceuticals Enters Licensing Agreement with Hikma's Middle East Division	23-08-21	MT
SK Biopharmaceuticals Continues to Report Losses in Q2	23-08-11	MT
SK Biopharmaceuticals Co., Ltd. agreed to acquire 60% interest in ProteoVant Sciences, Inc. from Roivant Sciences Ltd. for $47.5 million.	23-06-29	CI
SK Biopharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
SK Biopharmaceuticals Narrows Loss in Q1	23-05-12	MT
SK Biopharmaceuticals Swings to Loss in Q4	23-02-09	MT
SK Biopharmaceuticals Co. Ltd Partner Angelini Pharma Launches Cenobamate in France	22-12-08	CI
Seoul National University Bundang Hospital Presents Study of SK Biopharmaceuticals' Seizure Detection Wearable Device At AES 2022	22-12-04	CI
SK Biopharmaceuticals Receives Korea Drug Development Fund Investment Grant to Develop Novel Oncology Candidate, SKL27969	22-11-13	CI
SK Biopharmaceuticals, Co., Ltd., Eurofarma Enters into Licensing Agreement for Cenobamate in Latin America	22-07-14	CI
SK Biopharmaceuticals Swings to Loss in Q1	22-05-13	MT
Axsome Therapeutics to Buy Sunosi From Jazz Pharmaceuticals	22-03-28	DJ
BIORCHESTRA and SK Biopharmaceuticals Collaborate to Develop Mirna-Targeted Therapeutics	22-01-04	CI
SK Biopharmaceuticals Narrows Loss in Q3	21-11-12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights SK Biopharmaceuticals Co., Ltd.

Equities

A326030

KR7326030004

Highlights

Filters